Kalaris Therapeutics (NASDAQ:KLRS) Rating Lowered to Sell at Wall Street Zen

Kalaris Therapeutics (NASDAQ:KLRS) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Friday.

KLRS has been the subject of a number of other reports. Citizens Jmp started coverage on Kalaris Therapeutics in a research note on Monday, November 3rd. They issued a “market outperform” rating and a $20.00 price target for the company. Chardan Capital assumed coverage on shares of Kalaris Therapeutics in a research report on Tuesday, December 23rd. They issued a “buy” rating and a $19.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kalaris Therapeutics in a research note on Monday, December 29th. Finally, Citigroup restated an “outperform” rating on shares of Kalaris Therapeutics in a research note on Thursday, December 18th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $14.00.

Kalaris Therapeutics Stock Up 0.2%

Shares of KLRS opened at $9.80 on Friday. The company has a 50 day moving average of $8.13 and a two-hundred day moving average of $5.45. Kalaris Therapeutics has a twelve month low of $2.14 and a twelve month high of $12.90. The company has a market cap of $183.26 million, a price-to-earnings ratio of -2.60 and a beta of -0.09.

Kalaris Therapeutics (NASDAQ:KLRS) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.02.

Hedge Funds Weigh In On Kalaris Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. XTX Topco Ltd acquired a new stake in Kalaris Therapeutics during the second quarter worth about $65,000. Fortis Capital Advisors LLC purchased a new stake in Kalaris Therapeutics in the 3rd quarter worth approximately $231,000. Belpointe Asset Management LLC purchased a new stake in Kalaris Therapeutics in the 3rd quarter worth approximately $231,000. Johnson Financial Group Inc. acquired a new stake in shares of Kalaris Therapeutics during the 3rd quarter worth approximately $58,000. Finally, Bridgeway Capital Management LLC acquired a new stake in shares of Kalaris Therapeutics during the 3rd quarter worth approximately $130,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.